



February 27, 2025  
Announcement no. 03

## **Strengthening of Investor Focus - BioPorto enters Market Maker Agreement with Danske Bank & appoints New Head of Investor Relations**

COPENHAGEN, DENMARK, February 27, 2025, (GLOBE NEWSWIRE) - BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today announced that it has entered into a Market Maker Agreement with Danske Bank and appoints Hanne Søgaaard as Head of Investor Relations.

### **Market Maker Agreement with Danske Bank**

BioPorto has entered a market maker agreement with Danske bank effective 1 March 2025. The purpose of the Market Maker scheme is to create liquidity on Nasdaq Copenhagen in the listed share and can be summarized as follows:

- Danske Bank commits to continuously facilitate trading in the BioPorto shares by quoting prices, within a range considered acceptable, on either the buy or sell side in the market.
- Danske Bank's quotation is made without BioPorto's interference
- Purchases/sales are at Danske Bank's expense and risk

### **Appointment of Hanne Søgaaard as Head of Investor Relations**

Further, as part of BioPorto's continuous commitment to strengthen the Investor focus and promoting Investor Relations activities within the local investor community, the Company is pleased to announce that, effective 1 March 2025, Hanne Søgaaard will join BioPorto as the Company's new Head of Investor Relations.

Hanne brings extensive experience within Investor Relations and financial communication, having previously led Nykredit's Investor Relations and ESG initiatives. With a strong background in financial analysis and communication from her roles at Nykredit, Juristernes og Økonomernes Pensionskasse, Danske Markets, Skandia Pension, and Alm. Brand Forsikring, Hanne is well-suited to enhance our Investor Relations efforts communicating and engaging with investors on our strategy and helping drive our strategic goals forward.

*Niels Høy Nielsen, CFO of BioPorto, comments: "I am very pleased to welcome Hanne to our team. Her expertise and dedication will significantly strengthen our Investor Relations function, fostering greater transparency and a much stronger presence within our current investor community. Hanne will be instrumental in enhancing our communication with our current as well as potential new investors. This strategic addition is a testament to our commitment to continuously enhancing focus on our investors maintaining an open and effective dialogue. Furthermore, our market maker agreement with Danske Bank is set to enhance the liquidity of our shares on Nasdaq Copenhagen, providing our investors with an improved trading experience."*

To receive BioPorto's Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on <https://bioporto.com/investor-contact/>.

### **For investor inquiries, please contact:**

Niels Høy Nielsen, CFO, +45 4529 0000, [investor@bioporto.com](mailto:investor@bioporto.com)

## **About BioPorto**

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers - tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company's tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company's flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.

BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit [www.bioporto.com](http://www.bioporto.com).

## **Forward-looking statement disclaimer**

Certain statements in this news release are not historical facts and may be forward-looking statements. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the Company's expectations, intentions and projections regarding its future performance including the Company's Guidance for 2024; currency exchange rate fluctuations; anticipated events or trends and other matters that are not historical facts, including with respect to implementation of manufacturing and quality systems, commercialization of NGAL tests, and the development of future products and new indications; concerns that may arise from additional data, analysis or results obtained during clinical trials; and, the Company's ability to successfully market both new and existing products. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "intend", "estimate", "expect" and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, and uncertainties that could cause the actual results of operations, financial condition, liquidity, dividend policy and the development of the industry in which the Company's business operates to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Factors that may impact BioPorto's success are more fully disclosed in BioPorto's periodic financial filings, including its Annual Report for 2023, with the Danish Financial Supervisory Authority, particularly under the heading "Risk Factors".